BridgeBio Oncology Therapeutics Inc. (BBOT) annual income statement — 5-year revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - |
| Cost of Goods Sold | 186K | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | -186K | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - |
| Operating Expenses | 168.68M | 145.82M | 80.86M | 64.77M | 3.52K | 43.36K |
| OpEx % of Revenue | - | - | - | - | - | - |
| Selling, General & Admin | 28.5M | 24.62M | 7.76M | 8.48M | 3.52K | 43.36K |
| SG&A % of Revenue | - | - | - | - | - | - |
| Research & Development | 140.37M | 121.2M | 73.11M | 56.29M | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - | - |
| Other Operating Expenses | -186K | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -168.86M | -145.82M | -80.86M | -64.77M | -3.52K | -43.36K |
| Operating Margin % | - | - | - | - | - | - |
| Operating Income Growth % | - | -80.33% | -24.84% | -1839985.23% | 91.88% | - |
| EBITDA | -168.12M | -145.21M | -80.66M | -64.68M | -3.52K | -43.36K |
| EBITDA Margin % | - | - | - | - | - | - |
| EBITDA Growth % | -90.31% | -80.04% | -24.7% | -1837371.59% | 91.88% | - |
| D&A (Non-Cash Add-back) | 742K | 610K | 208K | 92K | 0 | 0 |
| EBIT | -168.86M | -145.82M | -80.86M | -64.77M | -3.52K | -43.36K |
| Net Interest Income | 13.89M | 11.34M | 8.46M | 72K | 0 | 0 |
| Interest Income | 13.89M | 11.34M | 8.46M | 72K | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 14.77M | 11.78M | 8.18M | 72K | 0 | 0 |
| Pretax Income | -154.09M | -134.04M | -74.28M | -64.7M | -3.52K | -43.36K |
| Pretax Margin % | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -154.09M | -134.04M | -74.28M | -64.7M | -3.52K | -43.36K |
| Net Margin % | - | - | - | - | - | - |
| Net Income Growth % | -90.5% | -80.47% | -14.8% | -1837939.77% | 91.88% | - |
| Net Income (Continuing) | -154.09M | -134.04M | 7.6M | -64.7M | -3.52K | -43.36K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -4.95 | -4.30 | 0.46 | -3.16 | -0.00 | -0.00 |
| EPS Growth % | -289.52% | -1034.78% | 114.56% | - | - | - |
| EPS (Basic) | - | -4.30 | 0.46 | -3.16 | 0.00 | -0.00 |
| Diluted Shares Outstanding | 31.14M | 31.14M | 16.64M | 20.48M | 20.48M | 20.48M |
| Basic Shares Outstanding | 31.14M | 31.14M | 16.64M | 20.48M | 20.48M | 20.48M |
| Dividend Payout Ratio | - | - | - | - | - | - |
Quick answers to the most common questions about buying BBOT stock.
For fiscal year 2025, BridgeBio Oncology Therapeutics Inc. (BBOT) reported total revenue of $0.0M.
BridgeBio Oncology Therapeutics Inc. (BBOT) reported a net loss of $134.0M for the fiscal year ending 2025.